Premenstrual disorders among young Turkish women: According to
            <i>DSM‐IV</i>
            and
            <i>DSM‐V</i>
            criteria using the premenstrual symptoms screening tool

Daşikan, Zeynep

doi:10.1111/ppc.12656

Cited by 4 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 In Turkey that was 79% PMS experiencing moderate to high level of it. 2 And also consistent in China with 76% of prevalence of PMS. 3 But the finding is inconsistent in Kolkata, where 54% of girls have PMS.…”

Section: Discussionsupporting

confidence: 66%

See 1 more Smart Citation

Prevalence of Premenstrual Syndrome among Adolescent Girls in the Selected Schools in Kathmandu, Nepal

Manandhar

Neupane²

2022

Nep. Med. Coll. J.

View full text Add to dashboard Cite

The global prevalence of premenstrual syndrome is 47.8%. This study was conducted to assess to assess prevalence of premenstrual syndrome among adolescent girl students among selected schools in Kathmandu. A descriptive cross sectional study was conducted among total 150 students. They were selected by using proportionate stratified random sampling technique. Data were collected using standard PMS scale (r =0.81) through self-administered method. Data were analyzed in SPSS version 16 using descriptive statistics and inferential statistics. The mean age and standard deviation was 14.43 years ± 1.143 years with range of 11-16 years among 150 respondents. Among them, majority of respondent (84.0%) had premenstrual syndrome. Assessment of severity of premenstrual syndrome found that the minority of respondents (0.6%) had mild, 54.7% had moderate, 24.0% had severe and 4.7% had very severe PMS. Premenstrual syndrome was significantly associated with family history of PMS (p=0.041), number of pads used per day during period (p=0.032), junk food consumption (p=0.007), physical exercise (p=0.020), experience of stress (p=0.006). Thus it can be concluded that, most of the adolescent girls have experienced PMS ranging from mild to very severe symptoms. Therefore, it would be good if school can organize regular screening program and adolescent girl’s friendly school environment to identify the problem on timely.

show abstract

Section: Discussionsupporting

confidence: 66%

“…1 The incidence of PMS worldwide also varies from mild (70%-95%), moderate PMS (20%-70%), and severe PMS(1%-20%). 2 There was highest and lowest prevalence in Asia (46.96%) and Europe (35.37%). 3 In Northern Ethiopia, PMS is quite high as 80-90% prevalance.…”

Section: Introductionmentioning

confidence: 96%

Prevalence of Premenstrual Syndrome among Adolescent Girls in the Selected Schools in Kathmandu, Nepal

Manandhar

Neupane²

2022

Nep. Med. Coll. J.

View full text Add to dashboard Cite

show abstract

“…Clinically, PMDD is characterized by significant emotional, physical, and behavioral distress during the late luteal phase that resolves after the onset of menses AGING [3]. Premenstrual disorders are likely to start at a younger age, particularly in adolescence [4,5]. Many risk factors contribute to the development of PMDD.…”

Section: Introductionmentioning

confidence: 99%

Gabrb2 knock-out mice exhibit double-directed PMDD-like symptoms: GABAAR subunits, neurotransmitter metabolism disruption, and allopregnanolone binding

Gao

Zhang

Sun

et al. 2022

Aging

View full text Add to dashboard Cite

Background: Premenstrual dysphoric disorder (PMDD) is a severe mood disorder with pathological changes rooted in GABRB2 copy number variation. Here, we aimed to elucidate the gene dose effect and allopregnanolone binding mechanism of Gabrb2 on possible PMDD-like and comorbid phenotypes in knockout mice. Methods: PMDD-like behaviors of Gabrb2-knockout mice were measured through various tests. Western Blot and ELISA were used to detect changes in the GABAAR subunits and related neurotransmitter changes in mice respectively for the internal mechanism. The response of mice to allopregnanolone (ALLO) was examined through an exogenous ALLO injection, then validated by the patch-clamp technique to elaborate the potential mechanism of ALLO-mediated GABAAR. Results: Gabrb2-knockout mice displayed changes in anxiety-like and depression-like emotions opposite to PMDD symptoms, changes in social, learning, and memory capacities similar to PMDD symptoms, and pain threshold changes opposite to PMDD symptoms. GABAAR δ subunit expression in the brains of the Gabrb2knockout mice was significantly higher than that of Wild-type mice (P<0.05). Gabrb2-knockout mice demonstrated neurotransmitter metabolism disturbance of GABA, Glu, acetylcholine, DA, norepinephrine, and epinephrine. Moreover, Gabrb2-knockout mice did not display the expected phenotypic effect after ALLO injection. Relative to WT mice, the knockout of the β2 subunit gene enhanced the agonistic effect of ALLO on GABAA receptors in cortical neuronal cells. Conclusions: GABAAR β 2 regulates PMDD-like behaviors. The ALLO binding site may not be located on β two subunits, abnormal δ and ε subunit expression in the mouse brain and the disturbance of neurotransmitters may result in ALLO sensitivity.

show abstract

The Effect of Yoga Therapy in Premenstrual Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials

Ranga,

Dev

2024

Journal of Obstetrics and Gynaecology Canada

View full text Add to dashboard Cite

Premenstrual disorders among young Turkish women: According to DSM‐IV and DSM‐V criteria using the premenstrual symptoms screening tool

Cited by 4 publications

References 25 publications

Prevalence of Premenstrual Syndrome among Adolescent Girls in the Selected Schools in Kathmandu, Nepal

Prevalence of Premenstrual Syndrome among Adolescent Girls in the Selected Schools in Kathmandu, Nepal

Gabrb2 knock-out mice exhibit double-directed PMDD-like symptoms: GABAAR subunits, neurotransmitter metabolism disruption, and allopregnanolone binding

The Effect of Yoga Therapy in Premenstrual Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials

Contact Info

Product

Resources

About